Filing Details
- Accession Number:
- 0001140361-25-027890
- Form Type:
- 3
- Zero Holdings:
- No
- Publication Time:
- 2025-07-29 21:00:46
- Reporting Period:
- 2025-07-29
- Filing Date:
- 2025-07-29
- Accepted Time:
- 2025-07-29 21:00:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1635088 | Roivant Sciences Ltd. | ROIV | Pharmaceutical Preparations (2834) | 981173944 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1647805 | Frank Torti | C/O Roivant Sciences Ltd. 7Th Floor, 50 Broadway London X0 SW1H 0DB | President And Vant Chair | No | No | No | No |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to Buy) | $11.03 | 2028-09-19 | 1,606,249 | 0 | Direct | |
| Common Shares | Stock Option (Right to Buy) | $11.50 | 2029-04-21 | 585,240 | 0 | Direct | |
| Common Shares | Stock Option (Right to Buy) | $10.08 | 2029-08-19 | 146,310 | 0 | Direct | |
| Common Shares | Stock Option (Right to Buy) | $13.07 | 2030-05-19 | 219,465 | 0 | Direct | |
| Common Shares | Stock Option (Right to Buy) | $10.00 | 2031-05-01 | 562,731 | 0 | Direct | |
| Common Shares | Stock Option (Right to Buy) | $10.00 | 2031-05-01 | 1,125,460 | 0 | Direct | |
| Common Shares | Stock Option (Right to Buy) | $3.85 | 2032-04-19 | 6,026,184 | 0 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2028-09-19 | 1,606,249 | 0 | Direct |
| 2029-04-21 | 585,240 | 0 | Direct |
| 2029-08-19 | 146,310 | 0 | Direct |
| 2030-05-19 | 219,465 | 0 | Direct |
| 2031-05-01 | 562,731 | 0 | Direct |
| 2031-05-01 | 1,125,460 | 0 | Direct |
| 2032-04-19 | 6,026,184 | 0 | Direct |
Footnotes
- Reflects an award of stock options to purchase Common Shares that is fully vested.
- Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).
Billionaire Hedge Funds
